Florian Lambracht - Taylor Wessing

Francfort Allemagne

Écrire Call me

Prix à l'honneur

Legal 500 2026

Recommended lawyer for Commercial Litigation

Florian is a litigation lawyer specialising in the MedTech/Pharma and Automotive sectors. He advises and represents companies in out-of-court and in-court dispute resolution. Florian Lambracht is an expert in product liability law issues and the defence of claims in mass proceedings using internally developed, tailor-made legal tech tools. He also has many years of in-house experience in pharmaceutical and automotive companies.

CV

Since 2024 Salary Partner, Taylor Wessing

2022 Senior Associate, Taylor Wessing

2019 Associate, Taylor Wessing

Carrière

Since 2024 Salary Partner, Taylor Wessing

2022 Senior Associate, Taylor Wessing

2019 Associate, Taylor Wessing

Formation

2019 Admitted as lawyer, Frankfurt a.M.

2019 Second judicial state examination, Frankfurt a.M.

2017 – 2019 Legal trainee solicitor, Higher Regional Court in Frankfurt a.M., the German Embassy in Stockholm, Sweden and Taylor Wessing

Langues étrangères

Prix et distinctions

Legal 500 2026

Featured

Legal 500 2026

Experience

COVID-19 vaccine product liability proceedings

Representing AstraZeneca in all product liability proceedings relating to its COVID-19 vaccine in Germany.

Dr. Henning Moelle, LL.M.

Dr. Lena Niehoff

Florian Lambracht

David Hilger, LL.M. (Bilbao)

Actualités et publications récentes

View Florian's insights

Cliquer ici pour en savoir plus

Résolution des litiges

Disputes Predictions – The litigation and arbitration issues companies must prepare for

26 février 2026

par plusieurs auteurs

Technologie, Médias et Communications (TMC)

What international businesses should know about the German AI Market Surveillance and Innovation Promotion Act

20 février 2026

Briefing

par plusieurs auteurs

Cliquer ici pour en savoir plus

Responsabilité du fait des produits et de la sécurité des produits

New guidance on the General Product Safety Regulation: a snapshot of key clarifications

21 novembre 2025

Quick read

par plusieurs auteurs

Cliquer ici pour en savoir plus